Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Share-based Compensation (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Share-based Compensation for 4 consecutive years, with $7.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 14.89% to $7.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $31.4 million, a 3.96% decrease, with the full-year FY2024 number at $33.5 million, up 14.13% from a year prior.
  • Share-based Compensation was $7.2 million for Q3 2025 at Centessa Pharmaceuticals, down from $7.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.6 million in Q2 2024 to a low of $5.6 million in Q2 2022.
  • A 4-year average of $7.4 million and a median of $7.4 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: increased 28.73% in 2023, then decreased 14.89% in 2025.
  • Centessa Pharmaceuticals' Share-based Compensation stood at $6.6 million in 2022, then grew by 12.29% to $7.4 million in 2023, then increased by 12.09% to $8.3 million in 2024, then dropped by 13.62% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Share-based Compensation are $7.2 million (Q3 2025), $7.9 million (Q2 2025), and $7.9 million (Q1 2025).